Patents by Inventor Yu-Sheng Chao

Yu-Sheng Chao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazole compounds as protein kinase inhibitors
    Patent number: 11299489
    Abstract: Thiazole compounds of Formula (I) shown below and pharmaceutical compositions containing one of such compounds: wherein R1 and R2 are defined in the specification. Also disclosed are methods of inhibiting a tyrosine kinase and treating cancer associated with a tyrosine kinase with one of the thiazole compounds.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: April 12, 2022
    Assignees: National Health Research Institutes, Taivex Therapeutics Corporation
    Inventors: Weir-Torn Jiaang, Yu-Sheng Chao
  • Heterocyclic compounds and use thereof
    Patent number: 9926298
    Abstract: Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 27, 2018
    Assignee: National Health Research Institutes
    Inventors: Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao
  • HETEROCYCLIC COMPOUNDS AND USE THEREOF
    Publication number: 20180009786
    Abstract: Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Inventors: Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao
  • Heterocyclic compounds and use thereof
    Patent number: 9862703
    Abstract: Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: January 9, 2018
    Assignee: National Health Research Institutes
    Inventors: Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao
  • Opioid receptor modulators and use thereof
    Patent number: 9827228
    Abstract: Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: November 28, 2017
    Assignees: National Health Research Institutes, Regents of the University of Minnesota
    Inventors: Shau-Hua Ueng, Shiu-Hwa Yeh, Horace Loh, Yu-Sheng Chao
  • OPIOID RECEPTOR MODULATORS AND USE THEREOF
    Publication number: 20170056377
    Abstract: Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.
    Type: Application
    Filed: July 12, 2016
    Publication date: March 2, 2017
    Inventors: Shau-Hua Ueng, Shiu-Hwa Yeh, Horace Loh, Yu-Sheng Chao
  • Dipicolylamine derivatives and their pharmaceutical uses
    Patent number: 9388193
    Abstract: Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: July 12, 2016
    Assignees: National Health Research Institutes, Molecular Targeting Technologies, Inc.
    Inventors: Chiung-Tong Chen, Kak-Shan Shia, Chien-Huang Wu, Lun-Kelvin Tsou, Yu-Sheng Chao
  • HETEROCYCLIC COMPOUNDS AND USE THEREOF
    Publication number: 20160083369
    Abstract: Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 24, 2016
    Inventors: Kak-Shan Shia, Jiing-Jyh Jan, Lun Kelvin Tsou, Chiung-Tong Chen, Yu-Sheng Chao
  • Pyrazole compounds and thiazole compounds as protein kinases inhibitors
    Patent number: 9255072
    Abstract: A compound of formula (I): wherein A, B, D, X, Y, R1, R2, R3, m, p, and q are defined herein. Also disclosed is a method for inhibiting FMS-like tyrosine kinase 3, aurora kinase, or vascular endothelial growth factor receptor.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 9, 2016
    Assignee: National Health Rsearch Institutes
    Inventors: Weir-Torn Jiaang, Tsu-An Hsu, Wen-Hsing Lin, Yu-Sheng Chao
  • DIPICOLYLAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USES
    Publication number: 20150336976
    Abstract: Dipicolylamine compounds of Formula (I) set forth herein. Also disclosed are pharmaceutical compositions containing metal ions and these compounds. Further disclosed is a method for treating a condition associated with cells containing inside-out phosphatidylserine, with these compounds.
    Type: Application
    Filed: May 14, 2015
    Publication date: November 26, 2015
    Inventors: Chiung-Tong Cheng, Kak-Shan Shia, Chien-Huang Wu, Lun-Kelvin Tsou, Yu-Sheng Chao
  • Fused multicyclic compounds as protein kinase inhibitors
    Patent number: 9006252
    Abstract: Fused multicyclic compounds of formula (I): wherein R?, R?, X, Y, Z, A, B, C, D, and n are defined herein. Also disclosed are a method for inhibiting protein kinase (e.g., Aurora kinase) activity and a method for treating a protein kinase mediated disorder (e.g., cancer) with these compounds.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: April 14, 2015
    Assignee: National Health Research Institutes
    Inventors: Hsing-Pang Hsieh, Selvaraj Mohane Coumar, Yu-Sheng Chao
  • Pyrazole compounds
    Patent number: 8962845
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, and X are defined herein. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: February 24, 2015
    Assignee: National Health Research Institutes
    Inventors: Kak-Shan Shia, Chun-Ping Chang, Yu-Sheng Chao
  • COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION
    Publication number: 20140127158
    Abstract: A method of treating hepatitis C virus infection, comprising administering to a subject in need thereof (a) an effective amount of at least one HCV inhibitor selected from the group consisting of an HCV NS3 inhibitor, an HCV NS5B inhibitor, ribavirin, and an IFN-?; and (b) an effective amount of an anti-HCV compound of formula (I).
    Type: Application
    Filed: November 6, 2013
    Publication date: May 8, 2014
    Applicant: National Health Research Institute
    Inventors: Andrew Yueh, Yu-Sheng Chao
  • Quinoline compounds and their use for treating viral infection
    Patent number: 8710079
    Abstract: Quinoline compounds of formula (I): in which A, B, D, E, F, G, R1, R2, R3, X, Y, n, p, and q are defined herein. Also disclosed is a method for treating a viral infection with a compound of formula (I).
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 29, 2014
    Assignee: National Health Research Institutes
    Inventors: Hsing-Pang Hsieh, Tsu-An Hsu, Jiann-Yih Yeh, Yu-Sheng Chao
  • Glycoside compounds
    Patent number: 8697658
    Abstract: Compounds of formula (I): wherein X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: April 15, 2014
    Assignee: National Health Research Institutes
    Inventors: Jinq-Chyi Lee, Yu-Sheng Chao
  • Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
    Patent number: 8507502
    Abstract: Fused bicyclic or tricyclic compounds of formula (I): wherein A, B, C, X, Y, m, and n are defined herein. Also disclosed are a method for inhibiting EGFR kinase activity and a method for treating cancer with these compounds.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: August 13, 2013
    Assignee: National Health Research Institutes
    Inventors: Hsing-Pang Hsieh, Selvaraj Mohane Coumar, Tsu-An Hsu, Wen-Hsing Lin, Yi-Rong Chen, Yu-Sheng Chao
  • Dibenzo[f,h]isoquinoline derivatives
    Patent number: 8486959
    Abstract: A group of novel dibenzo[f,h]isoquinoline derivatives as shown in the specification. Also disclosed are methods of using the compounds for treating a disease associated with NO overproduction, cancer, or viral infection.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 16, 2013
    Assignee: National Health Research Institutes
    Inventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee, Yu-Sheng Chao
  • Proline derivatives
    Patent number: 8415482
    Abstract: Compounds useful for treating hepatitis C virus infection. The compounds are of formula (I): wherein A, B, C, D, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, m, n, p, q, r, t, u, and v are defined herein. Also disclosed is a method for treating hepatitis C virus infection with these compounds.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: April 9, 2013
    Assignee: National Health Research Institutes
    Inventors: Jyh-Haur Chern, Yu-Sheng Chao
  • PYRAZOLE COMPOUNDS
    Publication number: 20130085126
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, and X are defined herein. Also disclosed are pharmaceutical compositions and methods related to use of these compounds.
    Type: Application
    Filed: September 25, 2012
    Publication date: April 4, 2013
    Applicant: National Health Research Institutes
    Inventors: Kak-Shan Shia, Chun-Ping Chang, Yu-Sheng Chao
  • Imidazol-4-one and imidazole-4-thione compounds
    Patent number: 8354442
    Abstract: Imidazol-4-one or imidazole-4-thione compounds of formula (I): wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: January 15, 2013
    Assignee: National Health Research Institutes
    Inventors: Kak-Shan Shia, Chien-Huang Wu, Teng-Kuang Yeh, Yu-Sheng Chao